Inclisiran dramatically lowered PCSK9 and LDL in ORION-1 trial | ACC

48% of patients who received 300-mg inclisiran regimen had an LDL level below 50 mg/dL at day 180.
48% of patients who received 300-mg inclisiran regimen had an LDL level below 50 mg/dL at day 180.